Open-label Extension Study Of RN624

Back to Search
Print
Bookmark Trial

NCT00399490

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmingham, Alabama, 35209, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Osteoarthritis, OA Knee Pain, Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Enrolled in Study RN624-CL006

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- The occurrence of any adverse event or condition during the controlled studies that,
in the opinion of the Investigator, should exclude the subject from participating in
the open-label extension


- Pregnant or lactating female subjects or subjects who do not agree to use an
appropriate form of birth control throughout the study and for 3 months after
completing the study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Osteoarthritis, OA Knee Pain, ArthritisOpen-label Extension Study Of RN624 NCT00399490
  1. Birmingham, Alabama
  2. Phoenix, Arizona
  3. Anaheim, California
  4. Cypress, California
  5. National City, California
  6. Stamford, Connecticut
  7. Daytona Beach, Florida
  8. Ocala, Florida
  9. Tampa, Florida
  10. Honolulu, Hawaii
  11. Boise, Idaho
  12. Merrillville, Indiana
  13. Louisville, Kentucky
  14. Wheaton, Maryland
  15. Worcester, Massachusetts
  16. Kansas City, Missouri
  17. Omaha, Nebraska
  18. Albuquerque, New Mexico
  19. Rochester, New York
  20. Greensboro, North Carolina
  21. Greensboro, North Carolina
  22. Zanesville, Ohio
  23. Duncansville, Pennsylvania
  24. Knoxville, Tennessee
  25. Austin, Texas
  26. San Antonio, Texas
  27. Midvale, Utah
  28. Charlottesville, Virginia
  29. Yakima, Washington
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Open-label Extension Study Of RN624
Official Title  ICMJE Open-Label, Multiple-Dose Study Of The Safety And Efficacy Of RN624 In Adults With Pain Due To Osteoarthritis Of The Knee
Brief Summary Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Osteoarthritis
  • OA Knee Pain
  • Arthritis
Intervention  ICMJE Drug: RN624 (PF-04383119)
50 mcg/kg
Study Arms  ICMJE Experimental: 1
Intervention: Drug: RN624 (PF-04383119)
Publications * Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011 Jun;19(6):639-46. doi: 10.1016/j.joca.2011.01.009. Epub 2011 Jan 18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 8, 2013)		281
Original Enrollment  ICMJE
 (submitted: November 14, 2006)		150
Actual Study Completion Date  ICMJE February 2008
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Enrolled in Study RN624-CL006

Exclusion Criteria:

  • The occurrence of any adverse event or condition during the controlled studies that, in the opinion of the Investigator, should exclude the subject from participating in the open-label extension
  • Pregnant or lactating female subjects or subjects who do not agree to use an appropriate form of birth control throughout the study and for 3 months after completing the study
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00399490
Other Study ID Numbers  ICMJE A4091009
RN624-CL007
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP